Results 41 to 50 of about 1,364 (160)

Disautonomia: Uma Condição Esquecida – Parte 1 [PDF]

Arquivos Brasileiros de Cardiologia
Resumo – Pontos Essenciais O termo disautonomia abrange um conjunto de condições clínicas com características e prognósticos distintos. Classificam-se em síndromes reflexas, síndrome postural ortostática taquicardizante (SPOT), síndrome da fadiga crônica,
Eduardo Arrais Rocha, Niraj Mehta, Maria Zildany Pinheiro Távora-Mehta, Camila Ferreira Roncari, Alan Alves de Lima Cidrão, Jorge Elias Neto   +5 more
doaj   +3 more sources

Central Involvement in Pure Autonomic Failure: Insights from Neuromelanin‐Sensitive Magnetic Resonance Imaging and 18F‐Fluorodopa‐Positron Emission Tomography

Movement Disorders, Volume 40, Issue 4, Page 716-726, April 2025.
Abstract Background Central synucleinopathies, including Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA), involve alpha‐synuclein accumulation and dopaminergic cell loss in the substantia nigra (SN) and locus coeruleus (LC).
Paula Trujillo, Kaitlyn R. O'Rourke, Olivia C. Roman, Alexander K. Song, Kilian Hett, Amy Cooper, Bonnie K. Black, Manus J. Donahue, Cyndya A. Shibao, Italo Biaggioni, Daniel O. Claassen   +10 more
wiley   +1 more source

Amyloid Neuropathy: From Pathophysiology to Treatment in Light‐Chain Amyloidosis and Hereditary Transthyretin Amyloidosis

Annals of Neurology, Volume 96, Issue 3, Page 423-440, September 2024.
Amyloid neuropathy is caused by deposition of insoluble β‐pleated amyloid sheets in the peripheral nervous system. It is most common in: (1) light‐chain amyloidosis, a clonal non‐proliferative plasma cell disorder in which fragments of immunoglobulin, light or heavy chain, deposit in tissues, and (2) hereditary transthyretin (ATTRv) amyloidosis, a ...
Pitcha Chompoopong, Michelle L. Mauermann, Hasan Siddiqi, Amanda Peltier   +3 more
wiley   +1 more source

Istradefylline/L‐DOPA Parkinson's disease therapy and energy coupling

Neurology and Clinical Neuroscience, Volume 12, Issue 5, Page 296-305, September 2024.
Abstract Background Both dopamine and adenosine are physiologically involved in cellular energy metabolism. Aim Novel approaches targeting delaying progression strategies for Parkinson's disease (PD) examined the effects of long‐term use of A2AR antagonist/istradefylline (IST) adjunct to L‐DOPA (LD), nutshell IST‐LD, with an expected energy coupling ...
Naomi Kanzato, Koh Nakachi, Satsuki Mochizuki   +2 more
wiley   +1 more source

Analysis of L-DOPA and Droxidopa Binding to Human Beta 2-Adrenergic Receptor [PDF]

, 2021
Andrea Catte, Akash Deep Biswas, Sara Del Galdo, Giordano Mancini, Vincenzo Barone   +4 more
openalex   +1 more source

Fix or Adapt? Rethinking the Management of Complex Autonomic Dysfunction in an Older Adult Following Orthopedic Surgery

Geriatrics &Gerontology International, EarlyView.
Calvin D. De Louche, Sudarshanie Palliyage   +1 more
wiley   +1 more source

Associations of vitamin D receptor activators and calcimimetics with falls and effect modifications by physical activity: A prospective cohort study on the Japan Dialysis Outcomes and Practice Patterns Study

Therapeutic Apheresis and Dialysis, Volume 28, Issue 4, Page 547-556, August 2024.
Abstract Introduction This study aimed to examine the associations of vitamin D receptor activators (VDRA) and calcimimetics use with falls. Methods This is a prospective cohort study on hemodialysis patients in the Japan Dialysis Outcomes and Practice Patterns Study. We excluded those who were unable to walk.
Miho Murashima, Ryohei Yamamoto, Eiichiro Kanda, Noriaki Kurita, Hisashi Noma, Takayuki Hamano, Masafumi Fukagawa   +6 more
wiley   +1 more source

Efficacy and Safety of Elobixibat in Parkinson's Disease with Chronic Constipation: CONST‐PD Study

Movement Disorders Clinical Practice, Volume 11, Issue 4, Page 352-362, April 2024.
Abstract Background Chronic constipation is a common digestive complication of Parkinson's disease (PD). Objectives To verify the usefulness of elobixibat, an ileal bile acid transporter inhibitor, for chronic constipation in PD. Methods This double‐blind, placebo‐controlled study consisted of a 2‐week observation/washout period and a 4‐week treatment ...
Taku Hatano, Genko Oyama, Yasushi Shimo, Kotaro Ogaki, Noriko Nishikawa, Ryota Nakamura, Taiji Tsunemi, Takashi Ogawa, Hiroto Eguchi, Kensuke Daida, Naohide Kurita, Shin‐ichi Ueno, Jiro Fukae, Wataru Sako, Kenta Shiina, Sho Nakajima, Yutaka Oji, Ryo Wakamori, Shinji Saiki, Kenya Nishioka, Ayami Okuzumi, Daisuke Taniguchi, Haruka Takeshige‐Amano, Atsuhito Fuse, Asuka Nakajima, Masayoshi Kano, Hikaru Kamo, Yuri Yamashita, Atsuhiko Shindo, Naotake Yanagisawa, Nobutaka Hattori   +30 more
wiley   +1 more source

Neurogenic orthostatic hypotension – management update and role of droxidopa

Therapeutics and Clinical Risk Management, 2015
Joy Vijayan,1 Vijay K Sharma1,21Department of Medicine, Division of Neurology, National University Health System, 2Yong Loo Lin School of Medicine, National University of Singapore, SingaporeAbstract: Orthostatic hypotension (OH) is defined as a ...
Vijayan J, Sharma VK
doaj  

Diagnosis and treatment of hereditary transthyretin amyloidosis with polyneuropathy in the United States: Recommendations from a panel of experts

Muscle &Nerve, Volume 69, Issue 3, Page 273-287, March 2024.
Abstract Hereditary transthyretin (ATTRv; v for variant) amyloidosis is a rare, multisystem, progressive, and fatal disease in which polyneuropathy is a cardinal manifestation. Due to a lack of United States (US)‐specific guidance on ATTRv amyloidosis with polyneuropathy, a panel of US‐based expert clinicians convened to address identification ...
Chafic Karam, Michelle L. Mauermann, Alejandra Gonzalez‐Duarte, Michelle C. Kaku, Senda Ajroud‐Driss, Thomas H. Brannagan III, Michael Polydefkis   +6 more
wiley   +1 more source